Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAV12 plus Gemcitabine in Metastatic Pancreatic Cancer
NCT00625586Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Apr 2008
- Primary completion
- Jan 2009
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of RAV12 in pancreatic cancer (PC), sponsored by MacroGenics. Started Apr 2008; status: terminated.
02
Drugs
RAV12
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00625586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625586.